Literature DB >> 10739755

Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins.

J B Whitfield1, L M Cullen, E C Jazwinska, L W Powell, A C Heath, G Zhu, D L Duffy, N G Martin.   

Abstract

The aim of this study was to assess and to compare the role of HFE polymorphisms and other genetic factors in variation in iron stores. Blood samples were obtained from 3,375 adult male and female twins (age range 29-82 years) recruited from the Australian Twin Registry. There were 1,233 complete pairs (562 monozygotic and 571 dizygotic twins). Serum iron, transferrin, transferrin saturation with iron, and ferritin were measured, and the HFE C282Y and H63D genotypes were determined. The frequency of the C282Y allele was.072, and that of the H63D allele was.141. Significant sources of variation in the indices of iron status included age, sex, age-sex interaction, body-mass index, and both the C282Y and H63D genotypes. The iron, transferrin, and saturation values of CC and CY subjects differed significantly, but the ferritin values did not. After correction for age and body-mass index, 23% and 31% of the variance in iron, 66% and 49% of the variance in transferrin, 33% and 47% of the variance in transferrin saturation, and 47% and 47% of the variance in ferritin could be explained by additive genetic factors, for men and women, respectively. HFE C282Y and H63D variation accounted for <5% of the corrected phenotypic variance, except for saturation (12% in women and 5% in men). We conclude that HFE CY and HD heterozygotes differ in iron status from the CC and HH homozygotes and that serum transferrin saturation is more affected than is serum ferritin. There are highly significant effects of other as-yet-unidentified genes on iron stores, in addition to HFE genotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739755      PMCID: PMC1288192          DOI: 10.1086/302862

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  40 in total

1.  Prevalence of hemochromatosis among 11,065 presumably healthy blood donors.

Authors:  C Q Edwards; L M Griffen; D Goldgar; C Drummond; M H Skolnick; J P Kushner
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

2.  Prevalence of haemochromatosis amongst asymptomatic Australians.

Authors:  B A Leggett; J W Halliday; N N Brown; S Bryant; L W Powell
Journal:  Br J Haematol       Date:  1990-04       Impact factor: 6.998

3.  Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes.

Authors:  R S Ajioka; L B Jorde; J R Gruen; P Yu; D Dimitrova; J Barrow; E Radisky; C Q Edwards; L M Griffen; J P Kushner
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation : a prospective cohort study in men in eastern Finland.

Authors:  T P Tuomainen; K Kontula; K Nyyssönen; T A Lakka; T Heliö; J T Salonen
Journal:  Circulation       Date:  1999-09-21       Impact factor: 29.690

5.  Compound heterozygotes for hemochromatosis gene mutations: may they help to understand the pathophysiology of the disease?

Authors:  P Aguilar Martinez; C Biron; F Blanc; C Masmejean; P Jeanjean; H Michel; J F Schved
Journal:  Blood Cells Mol Dis       Date:  1997-08       Impact factor: 3.039

Review 6.  Iron in liver diseases other than hemochromatosis.

Authors:  H L Bonkovsky; B F Banner; R W Lambrecht; R B Rubin
Journal:  Semin Liver Dis       Date:  1996-02       Impact factor: 6.115

7.  Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study.

Authors:  S Kiechl; J Willeit; G Egger; W Poewe; F Oberhollenzer
Journal:  Circulation       Date:  1997-11-18       Impact factor: 29.690

8.  Clinical and biochemical abnormalities in people heterozygous for hemochromatosis.

Authors:  Z J Bulaj; L M Griffen; L B Jorde; C Q Edwards; J P Kushner
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

Review 9.  Iron as a hepatotoxin.

Authors:  P Stål
Journal:  Dig Dis       Date:  1995 Jul-Aug       Impact factor: 2.404

10.  Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark.

Authors:  A W Hsing; J K McLaughlin; J H Olsen; L Mellemkjar; S Wacholder; J F Fraumeni
Journal:  Int J Cancer       Date:  1995-01-17       Impact factor: 7.396

View more
  54 in total

1.  Of metals, mice, and men: what animal models can teach us about body iron loading.

Authors:  G J Anderson; L W Powell
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Transforming growth factor-beta(1) expression in dilated cardiomyopathy.

Authors:  J E Sanderson; K B Lai; I O Shum; S Wei; L T Chow
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

3.  Idiopathic dilated cardiomyopathy: lack of association with haemochromatosis gene in the CARDIGENE study.

Authors:  G Hetet; B Grandchamp; C Bouchier; V Nicaud; L Tiret; G Roizès; M Desnos; K Schwartz; R Dorent; M Komajda
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

4.  Contrast enhanced magnetic resonance angiography and pulmonary venous anomalies.

Authors:  F Godart; S Willoteaux; C Rey; B Cocheteux; C Francart; J P Beregi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

5.  Effects of cardiac resynchronisation on maximal and submaximal exercise performance in advanced heart failure patients with conduction abnormality.

Authors:  D Birnie; L P Soucie; S Smith; A S Tang
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

6.  Reciprocal increase of circulating interleukin-10 and interleukin-6 in patients with acute myocardial infarction.

Authors:  N Kotajima; T Kimura; T Kanda; A Kuwabara; Y Fukumura; M Murakami; I Kobayashi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

7.  Percutaneous aortic valve replacement: will we get there?

Authors:  Y Boudjemline; P Bonhoeffer
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

8.  Tetrahydrobiopterin attenuates cholesterol induced coronary hyperreactivity to endothelin.

Authors:  S Verma; A S Dumont; A Maitland
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

9.  Identification of a common variant in the TFR2 gene implicated in the physiological regulation of serum iron levels.

Authors:  Irene Pichler; Cosetta Minelli; Serena Sanna; Toshiko Tanaka; Christine Schwienbacher; Silvia Naitza; Eleonora Porcu; Cristian Pattaro; Fabio Busonero; Alessandra Zanon; Andrea Maschio; Scott A Melville; Maria Grazia Piras; Dan L Longo; Jack Guralnik; Dena Hernandez; Stefania Bandinelli; Elmar Aigner; Anthony T Murphy; Victor Wroblewski; Fabio Marroni; Igor Theurl; Carsten Gnewuch; Eric Schadt; Manfred Mitterer; David Schlessinger; Luigi Ferrucci; Derrick R Witcher; Andrew A Hicks; Günter Weiss; Manuela Uda; Peter P Pramstaller
Journal:  Hum Mol Genet       Date:  2010-12-28       Impact factor: 6.150

10.  Clinical penetrance of C282Y homozygous HFE haemochromatosis.

Authors:  Enrico Rossi; Gary P Jeffrey
Journal:  Clin Biochem Rev       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.